Alternatives to NanoZymeX
NanoZymeX is a Biotechnology tool: developing a lipid nanoparticle platform for enhanced enzyme replacement therapy. Here are the 60 closest alternatives, compared on pricing, features and what real users say.
The 20 closest Biotechnology companies to NanoZymeX
- Website
Epicrispr Biotechnologies62BiotechnologySouth San Francisco, United States$90.0MEpicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
- Website
Laverock Therapeutics41BiotechnologyCambridge, United Kingdom$10.0MDeveloping disease-responsive advanced therapies through programmable gene control technology.
- Website
Moderna77BiotechnologyCambridge, United States$4.5BModerna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
- Website
CRISPR Therapeutics64BiotechnologyZug, Switzerland$547.0MBiotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.
- Website
LifeMine Therapeutics Inc.60BiotechnologyWatertown, United States$543.0MClinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.
- Website
CellCentric60BiotechnologyCambridge, United Kingdom$375.0MA clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
- Website
Spark Therapeutics58BiotechnologyPhiladelphia, United States$82.8MA biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.
- Website
BreezeBio58BiotechnologyAlameda, US$93.5MBreezeBio is a genetic medicine company developing a pipeline of precision therapeutics.
- Website
Rocket Pharmaceuticals57BiotechnologyCranbury, USA$382.9MA biotechnology company developing genetic therapies for rare disorders.
- Website
Verve Therapeutics56BiotechnologyCambridge, USA$300.0MDeveloping gene editing therapies to lower cholesterol.
- Website
Anagram Therapeutics55BiotechnologyNatick, USA$285.0MClinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.
- Website
Latus Bio54BiotechnologyBoston, USA$151.0MEngineering scalable gene therapies for broader patient populations.
- Website
Transcripta Bio54BiotechnologyPalo Alto, United States$24.0MAI-powered drug discovery company focused on neurological and neuromuscular diseases, leveraging transcriptomics to accelerate therapeutic development.
- Website
Sinopia Biosciences54BiotechnologySan Diego, USA$2.2MBiotechnology company advancing novel therapeutics using its proprietary LEADS drug discovery platform.
- Website
Lightcast53BiotechnologyCambridge, United Kingdom$27.0MAI-powered antibody discovery platform.
- Website
Alloy Therapeutics51BiotechnologyBoston, USA$157.0MA biotechnology ecosystem company powering the future of drug discovery and development through AI-driven platforms and integrated services.
- Website
Travere Therapeutics51BiotechnologySan Diego, USA$63.0MA biopharmaceutical company focused on developing and commercializing therapies for rare diseases.
- Website
ONWARD Medical50BiotechnologyEindhoven, Netherlands$171.2MNeuroTech company developing therapies to restore movement and independence for people with spinal cord injuries.
- Website
mbiomics48BiotechnologyMunich, Germany$12.0MAdvancing scalable microbiome-based therapeutics for severe and chronic diseases.
- Website
Immitra Bio48BiotechnologyZürich, Switzerland$2.6MScalable, one-time curative in-vivo gene editing therapies.
Showing the 20 closest matches. See the rest on the NanoZymeX profile.